Gilead Sciences, Inc.
GILD
$120.14
$0.120.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.86B | 28.73B | 28.75B | 28.30B | 27.80B |
| Total Other Revenue | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M |
| Total Revenue | 28.86B | 28.74B | 28.75B | 28.30B | 27.80B |
| Cost of Revenue | 6.20B | 6.24B | 6.25B | 6.28B | 6.27B |
| Gross Profit | 22.67B | 22.50B | 22.50B | 22.02B | 21.53B |
| SG&A Expenses | 5.85B | 5.86B | 6.00B | 5.72B | 5.63B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.86B | 17.81B | 18.09B | 17.66B | 17.62B |
| Operating Income | 11.01B | 10.93B | 10.66B | 10.64B | 10.19B |
| Income Before Tax | 7.20B | 6.83B | 691.00M | 177.00M | 1.54B |
| Income Tax Expenses | 890.00M | 860.00M | 211.00M | 63.00M | 506.00M |
| Earnings from Continuing Operations | 6.31K | 5.97K | 480.00 | 114.00 | 1.03K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | 12.00M | 20.00M |
| Net Income | 6.31B | 5.97B | 480.00M | 126.00M | 1.05B |
| EBIT | 11.01B | 10.93B | 10.66B | 10.64B | 10.19B |
| EBITDA | 13.78B | 13.70B | 13.43B | 13.40B | 12.94B |
| EPS Basic | 5.06 | 4.78 | 0.38 | 0.10 | 0.84 |
| Normalized Basic EPS | 5.17 | 5.12 | 5.00 | 5.00 | 4.81 |
| EPS Diluted | 5.01 | 4.74 | 0.35 | 0.08 | 0.81 |
| Normalized Diluted EPS | 5.13 | 5.09 | 4.98 | 4.98 | 4.79 |
| Average Basic Shares Outstanding | 4.99B | 4.99B | 4.99B | 4.99B | 4.99B |
| Average Diluted Shares Outstanding | 5.03B | 5.02B | 5.01B | 5.01B | 5.01B |
| Dividend Per Share | 3.12 | 3.10 | 3.08 | 3.06 | 3.04 |
| Payout Ratio | 62.75% | 66.02% | 816.25% | 3,085.71% | 366.38% |